Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma

European Journal of Clinical Pharmacology

Volumn 67, Issue 10, 2011, Pages 993-1006

  Faganel Kotnik, Barbara ^a   Grabnar, Iztok ^b   Bohanec Grabar, Petra ^b   Dolžan, Vita ^b   Jazbec, Janez ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Acute lymphoblastic leukaemia; Children; Methotrexate; Pharmacogenetics; Population pharmacokinetics; Toxicity

Indexed keywords

FOLIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG MEGADOSE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHIONINE SYNTHASE GENE; METHIONINE SYNTHASE REDUCTASE GENE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE PROTEIN 1 GENE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED FOLATE CARRIER 1 GENE; REGULATOR GENE; THROMBOCYTOPENIA; THYMIDYLATE SYNTHASE GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD, PRESCHOOL; FEMALE; FOLIC ACID; GENOTYPE; HUMANS; LYMPHOMA; MALE; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUCOSITIS; NONLINEAR DYNAMICS; ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REDUCED FOLATE CARRIER PROTEIN; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 80054755097     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1046-z     Document Type: Article

References (54)

1. A Reiter M Schrappe M Tiemann WD Ludwig E Yakisan M Zimmermann G Mann A Chott W Ebell T Klingebiel N Graf B Kremens S Muller-Weihrich HJ Pluss F Zintl G Henze H Riehm 1999 Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt- Munster Group Trial NHL-BFM 90 Blood 94 10 3294 3306 10552938 1:CAS:528:DyaK1MXnsVagtb8%3D (Pubitemid 29536122)
2. M Schrappe A Reiter WD Ludwig J Harbott M Zimmermann W Hiddemann C Niemeyer G Henze A Feldges F Zintl B Kornhuber J Ritter K Welte H Gadner H Riehm 2000 Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group Blood 95 11 3310 3322 10828010 1:CAS:528:DC%2BD3cXjsl2isrs%3D (Pubitemid 30428458)
3. WE Evans MV Relling JH Rodman WR Crom JM Boyett CH Pui 1998 Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia N Engl J Med 338 8 499 505 9468466 10.1056/NEJM199802193380803 1:CAS:528:DyaK1cXhsVGju7s%3D (Pubitemid 28103133)
4. JA Moscow M Gong R He MK Sgagias KH Dixon SL Anzick PS Meltzer KH Cowan 1995 Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells Cancer Res 55 17 3790 3794 7641195 1:CAS:528: DyaK2MXnvVelsbk%3D
5. R Gorlick E Goker T Trippett M Waltham D Banerjee JR Bertino 1996 Intrinsic and acquired resistance to methotrexate in acute leukemia N Engl J Med 335 14 1041 1048 8793930 10.1056/NEJM199610033351408 1:CAS:528: DyaK28XmsFWlsL8%3D (Pubitemid 26338736)
6. R Takatori KA Takahashi D Tokunaga T Hojo M Fujioka T Asano T Hirata Y Kawahito Y Satomi H Nishino T Tanaka Y Hirota T Kubo 2006 ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients Clin Exp Rheumatol 24 5 546 554 17181924 1:STN:280: DC%2BD28jktlGgtQ%3D%3D (Pubitemid 44911249)
7. JR Whetstine AJ Gifford T Witt XY Liu RM Flatley M Norris M Haber JW Taub Y Ravindranath LH Matherly 2001 Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers Clin Cancer Res 7 11 3416 3422 11705857 1:CAS:528:DC%2BD3MXptFaisro%3D (Pubitemid 33069975)
8. N Horie H Aiba K Oguro H Hojo K Takeishi 1995 Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase Cell Struct Funct 20 3 191 197 7586009 10.1247/csf.20.191 1:CAS:528:DyaK2MXnvF2rsLg%3D
9. P Frosst HJ Blom R Milos P Goyette CA Sheppard RG Matthews GJ Boers M den Heijer LA Kluijtmans LP van den Heuvel, et al. 1995 A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase Nat Genet 10 1 111 113 7647779 10.1038/ng0595-111 1:CAS:528: DyaK2MXlsVymt78%3D
10. I Weisberg P Tran B Christensen S Sibani R Rozen 1998 A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity Mol Genet Metab 64 3 169 172 9719624 10.1006/mgme.1998.2714 1:CAS:528:DyaK1cXlvVygsrs%3D (Pubitemid 28453294)
11. D Leclerc E Campeau P Goyette CE Adjalla B Christensen M Ross P Eydoux DS Rosenblatt R Rozen RA Gravel 1996 Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders Hum Mol Genet 5 12 1867 1874 8968737 10.1093/hmg/5.12.1867 1:CAS:528:DyaK28XnsFKlt78%3D (Pubitemid 26413628)
12. DJ Gaughan LA Kluijtmans S Barbaux D McMaster IS Young JW Yarnell A Evans AS Whitehead 2001 The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations Atherosclerosis 157 2 451 456 11472746 10.1016/S0021-9150(00)00739-5 1:CAS:528:DC%2BD3MXltlOjt7o%3D (Pubitemid 32710025)
13. C Marzolini E Paus T Buclin RB Kim 2004 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 1 13 33 14749689 10.1016/j.clpt.2003.09.012 1:CAS:528:DC%2BD2cXntVKiuw%3D%3D (Pubitemid 38130115)
14. MH Cheok WE Evans 2006 Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy Nat Rev Cancer 6 2 117 129 16491071 10.1038/nrc1800 1:CAS:528:DC%2BD28Xht1eiu7g%3D (Pubitemid 43361544)
15. D Aumente DS Buelga JC Lukas P Gomez A Torres MJ Garcia 2006 Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia Clin Pharmacokinet 45 12 1227 1238 17112298 10.2165/00003088- 200645120-00007 1:CAS:528:DC%2BD2sXnt1enuw%3D%3D (Pubitemid 44904825)
16. C Piard F Bressolle M Fakhoury D Zhang K Yacouben A Rieutord E Jacqz-Aigrain 2007 A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia Cancer Chemother Pharmacol 60 4 609 620 17195068 10.1007/s00280-006- 0394-3 1:CAS:528:DC%2BD2sXnvFKnsbc%3D (Pubitemid 47084260)
17. A Rousseau C Sabot N Delepine G Delepine J Debord G Lachatre P Marquet 2002 Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma Clin Pharmacokinet 41 13 1095 1104 12403645 10.2165/00003088-200241130-00006 1:CAS:528:DC%2BD38XovFait7s%3D (Pubitemid 35246783)
18. A Moricke A Reiter M Zimmermann H Gadner M Stanulla M Dordelmann L Loning R Beier WD Ludwig R Ratei J Harbott J Boos G Mann F Niggli A Feldges G Henze K Welte JD Beck T Klingebiel C Niemeyer F Zintl U Bode C Urban H Wehinger D Niethammer H Riehm M Schrappe 2008 Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood 111 9 4477 4489 18285545 10.1182/blood-2007-09-112920
19. A Reiter M Schrappe WD Ludwig W Hiddemann S Sauter G Henze M Zimmermann F Lampert W Havers D Niethammer, et al. 1994 Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86 Blood 84 9 3122 3133 7949185 1:CAS:528: DyaK2MXhslOltbg%3D (Pubitemid 24328106)
20. ALL IC-BFM 2002-Trial Steering Committee (2002) A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia final version of therapy protocol from May 3, 2002. ALL IC-BFM 2002-Trial Steering Committee
21. A Reiter M Tiemann WD Ludwig HH Wacker E Yakisan M Schrappe D Henzler KW Sykora A Brandt E Odenwald, et al. 1994 NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 1: classification and allocation to strategic therapy groups. BIF study group Klin Pädiatr 206 4 222 233 7967418 10.1055/s-2008-1046608 1:STN:280: DyaK2M%2Fls12itQ%3D%3D
22. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer-treatment Cancer 47 1 207 214 7459811 10.1002/1097-0142(19810101)47: 1<207::AID-CNCR2820470134>3.0.CO;2-6 1:STN:280:DyaL3M7htFOltw%3D%3D (Pubitemid 11167383)
23. SA Miller DD Dykes HF Polesky 1988 A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res 16 3 1215 1215 3344216 10.1093/nar/16.3.1215 1:CAS:528:DyaL1cXhsVKlsrs%3D
24. GM Shaw EJ Lammer HP Zhu MW Baker E Neri RH Finnell 2002 Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida Am J Med Genet 108 1 1 6 11857541 10.1002/ajmg.10195 (Pubitemid 34101374)
25. PF Jacques AG Bostom J Selhub S Rich RC Ellison JH Eckfeldt RA Gravel R Rozen 2003 Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study Atherosclerosis 166 1 49 55 12482550 10.1016/S0021-9150(02)00204-6 1:CAS:528:DC%2BD38XptlCqu7Y%3D (Pubitemid 35449600)
26. K Matsuo R Suzuki N Hamajima M Ogura Y Kagami H Taji E Kondoh S Maeda S Asakura S Kaba S Nakamura M Seto Y Morishima K Tajima 2001 Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma Blood 97 10 3205 3209 11342450 10.1182/blood.V97.10.3205 1:CAS:528:DC%2BD3MXjsl2ru7Y%3D
27. B Iacopetta F Grieu D Joseph H Elsaleh 2001 A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil Br J Cancer 85 6 827 830 11556832 10.1054/bjoc.2001.2007 1:CAS:528:DC%2BD3MXpt1KisLY%3D (Pubitemid 33010548)
28. M Kurzawski A Pawlik W Gornik M Drodzik 2006 Frequency of common MDR1 gene variants in a Polish population Pharmacol Rep 58 1 35 40 16531628 1:CAS:528:DC%2BD28XlvVOhur4%3D
29. PB Grabar D Logar B Lestan V Dolzan 2008 Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism Eur J Clin Pharmacol 64 11 1057 1068 10.1007/s00228-008-0521-7
30. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2009) Prediction corrected visual predictive checks. Paper presented at the American Conference on Pharmacometrics (ACoP), Mashantucket, CT, USA. Available at: http://2009.go-acop.org/acop2009/posters. Accessed 24 Feb 2011
31. P Bohanec Grabar J Jazbec V Dolzan 2007 Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children Leuk Lymphoma 48 4 786 792 10.1080/10428190601187711 (Pubitemid 46605552)
32. CH Pui WE Evans 2006 Treatment of acute lymphoblastic leukemia N Engl J Med 354 2 166 178 16407512 10.1056/NEJMra052603 1:CAS:528:DC%2BD28XisFWksQ%3D%3D (Pubitemid 43076714)
33. Cunningham L, Aplenc R (2008) Role of the folate-pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response. In: Innocenti F (ed) Cancer drug discovery and development: genomics and pharmacogenomics in anticancer drug development and clinical response. Humana Press, Totowa, pp 299-309
34. K Schmiegelow 2009 Advances in individual prediction of methotrexate toxicity: a review Br J Haematol 146 5 489 503 19538530 10.1111/j.1365-2141. 2009.07765.x 1:CAS:528:DC%2BD1MXhtFeqtLjN
35. G Gervasini 2009 Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising Curr Drug Metab 10 6 547 566 19702537 1:CAS:528:DC%2BD1MXhsVSku7bL
36. YI Kim 2009 Role of the MTHFR polymorphisms in cancer risk modification and treatment Future Oncol 5 4 523 542 19450180 10.2217/fon.09.26 1:CAS:528:DC%2BD1MXmtF2qurc%3D
37. MV Relling D Fairclough D Ayers WR Crom JH Rodman CH Pui WE Evans 1994 Patient characteristics associated with high-risk methotrexate concentrations and toxicity J Clin Oncol 12 8 1667 1672 8040679 1:STN:280:DyaK2czhsFeqsg%3D%3D (Pubitemid 24245003)
38. AM Wall A Gajjar A Link H Mahmoud CH Pui MV Relling 2000 Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia Leukemia 14 2 221 225 10673736 10.1038/sj.leu.2401673 1:CAS:528: DC%2BD3cXhs1emtLs%3D (Pubitemid 30095374)
39. DW Faltaos JS Hulot S Urien V Morel G Kaloshi C Fernandez H Xuan V Leblond P Lechat 2006 Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy Cancer Chemother Pharmacol 58 5 626 633 16528531 10.1007/s00280-006-0202-0 1:CAS:528:DC%2BD28Xns1SmsLY%3D (Pubitemid 44167388)
40. S Monjanel-Mouterde C Lejeune J Ciccolini N Merite D Hadjaj P Bonnier P Piana A Durand 2002 Bayesian population model of methotrexate to guide dosage adjustments for folate rescue in patients with breast cancer J Clin Pharm Ther 27 3 189 195 12081632 10.1046/j.1365-2710.2002.00402.x 1:CAS:528: DC%2BD38XlslKqtbg%3D (Pubitemid 34748143)
41. MA Batey JG Wright A Azzabi DR Newell MJ Lind AH Calvert AV Boddy 2002 Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) Eur J Cancer 38 8 1081 1089 12008196 10.1016/S0959-8049(02) 00024-2 1:CAS:528:DC%2BD38Xjtl2mtL0%3D (Pubitemid 34468013)
42. C Laverdiere S Chiasson I Costea A Moghrabi M Krajinovic 2002 Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia Blood 100 10 3832 3834 12411325 10.1182/blood.V100.10.3832 (Pubitemid 35303961)
43. H Imanishi N Okamura M Yagi Y Noro Y Moriya T Nakamura A Hayakawa Y Takeshima T Sakaeda M Matsuo K Okumura 2007 Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma J Hum Genet 52 2 166 171 17180579 10.1007/s10038-006-0096-z 1:CAS:528:DC%2BD2sXhtFWitrk%3D (Pubitemid 46188292)
44. L Huang WJ Tissing R de Jonge BD van Zelst R Pieters 2008 Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia Leukemia 22 9 1798 1800 18368069 10.1038/leu.2008.66 1:CAS:528:DC%2BD1cXhtVyqu7zM
45. M Kantar B Kosova N Cetingul S Gumus E Toroslu N Zafer N Topcuoglu S Aksoylar M Cinar A Tetik Z Eroglu 2009 Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma Leuk Lymphoma 50 6 912 917 19391036 10.1080/10428190902893819 1:CAS:528:DC%2BD1MXntFChtr0%3D
46. PB van Kooten Niekerk K Schmiegelow H Schroeder 2008 Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate Eur J Haematol 81 5 391 398 18691257
47. S Kishi J Griener C Cheng S Das EH Cook D Pei M Hudson J Rubnitz JT Sandlund CH Pui MV Relling 2003 Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia J Clin Oncol 21 16 3084 3091 12915598 10.1200/JCO.2003.07.056 1:CAS:528:DC%2BD2cXpsVWqtLg%3D (Pubitemid 46606289)
48. K Seidemann M Book M Zimmermann U Meyer K Welte M Stanulla A Reiter 2006 MTHFR 677 ©- gt; T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95 Ann Hematol 85 5 291 300 16463153 10.1007/s00277-005-0072-2 1:CAS:528:DC%2BD28Xks1OktLw%3D (Pubitemid 43732651)
49. N Shimasaki T Mori H Samejima R Sato H Shimada N Yahagi C Torii H Yoshihara Y Tanigawara T Takahashi K Kosaki 2006 Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma J Pediatr Hematol /Oncol 28 2 64 68 10.1097/01.mph.0000198269.61948.90 1:CAS:528:DC%2BD28XisF2qs7k%3D
50. N Shimasaki T Mori C Torii R Sato H Shimada Y Tanigawara K Kosaki T Takahashi 2008 Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma J Pediatr Hematol/Oncol 30 5 347 352 10.1097/MPH.0b013e318165b25d 1:CAS:528:DC%2BD1cXmvVSnsbk%3D (Pubitemid 351643456)
51. B Faganel Kotnik V Dolzan I Grabnar J Jazbec 2010 Relationship of the reduced folate carrier gene polymorphism G80A to methotrexate plasma concentration, toxicity, and disease outcome in childhood acute lymphoblastic leukemia Leuk Lymphoma 51 4 724 726 20141435 10.3109/10428191003611402 1:CAS:528:DC%2BC3cXkt1ans7w%3D
52. M Krajinovic I Costea M Primeau S Dulucq A Moghrabi 2005 Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis Pharmacogenomics J 5 6 374 380 16130010 10.1038/sj.tpj.6500332 1:CAS:528:DC%2BD2MXht1GisLzI
53. LR Trevino N Shimasaki W Yang JC Panetta C Cheng D Pei D Chan A Sparreboom KM Giacomini CH Pui WE Evans MV Relling 2009 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects J Clin Oncol 27 35 5972 5978 19901119 10.1200/JCO.2008.20.4156 1:CAS:528:DC%2BC3cXhtVWisLw%3D
54. T Rau B Erney R Gores T Eschenhagen J Beck T Langer 2006 High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations Clin Pharmacol Ther 80 5 468 476 17112803 10.1016/j.clpt.2006.08.012 1:CAS:528:DC%2BD28Xht1elsrbJ (Pubitemid 44737489)